[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633211":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":63,"collaborators":22,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":22,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":22,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":47,"whyStopped":22,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Beijing Tongren Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PPS group","EXPERIMENTAL","All enrolled patients may initiate induction therapy after completing baseline imaging and relevant laboratory examinations:\n\nPomalidomide: 4 mg on days 1-14, every 3 weeks (q3w), for a total of 6 cycles; Selinexor: 60 mg on days 1, 8, and 15, q3w, for a total of 6 cycles; PD-1 monoclonal antibody: tislelizumab 200 mg on day 1, q3w, for a total of 6 cycles.\n\nDuring induction therapy, patients who achieve complete response (CR) may discontinue from the study to receive consolidation therapy with autologous hematopoietic stem cell transplantation (AHSCT) or dose-optimized whole-brain radiotherapy (WBRT), at the investigator's discretion or the patient's choice.\n\nFor patients not discontinuing for consolidation therapy, maintenance therapy may be administered after 6 cycles of induction therapy: pomalidomide 4 mg every other day (qod) plus selinexor 40-60 mg once weekly (qw), until disease progression or unacceptable toxicity.",[13,14,15],"Drug: Pomalidomide","Drug: PD-1 \u002F PD-L1 monoclonal antibody","Drug: XPO1 inhibitor",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Pomalidomide","4 mg on days 1-14, every 3 weeks (q3w), for a total of 6 cycles",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"PD-1 \u002F PD-L1 monoclonal antibody","tislelizumab 200 mg on day 1, q3w, for a total of 6 cycles",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"XPO1 inhibitor","Selinexor: 60 mg on days 1, 8, and 15, q3w, for a total of 6 cycles",[9],[32],{"name":33,"affiliation":5,"role":34},"Liang Wang, M.D.","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":22,"email":39},"CONTACT","+861058266633","wangliangtrhos@126.com",{"name":41,"role":37,"phone":42,"phoneExt":22,"email":43},"Jia Cong, M.D.","+861058268442","congjia21@163.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Beijing Tongren Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60,61,62],{"name":33,"role":37,"phone":38,"phoneExt":22,"email":39},{"name":41,"role":37,"phone":42,"phoneExt":22,"email":43},{"name":33,"role":34,"phone":22,"phoneExt":22,"email":22},{"type":34,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"LIANG WANG","Director of Department of Hematology in Beijing Tongren Hospital","100633211","phase-2-pomalidomide-anti-pd-1-antibody-combined-with-selinexor-pps-in-relapsedrefractory-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-100633211",false,"NCT07523737","Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed\u002FRefractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed\u002FRefractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Study","Inclusion Criteria:\n\n* Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).\n* Disease progression or relapse after prior treatment with high-dose methotrexate and\u002For BTK inhibitors.\n* Age between 18 and 75 years.\n* ECOG performance status score 0-4.\n* Expected overall survival \\> 3 months.\n* No known hypersensitivity to any study drug.\n* White blood cell count ≥ 3×10⁹\u002FL; absolute neutrophil count ≥ 1.0×10⁹\u002FL; platelet count ≥ 50×10⁹\u002FL.\n* Serum creatinine ≤ 1.5 mg\u002FdL; creatinine clearance ≥ 50 mL\u002Fmin.\n* ALT and AST ≤ 3× upper limit of normal (ULN); total bilirubin ≤ 2× ULN.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Presence of another malignant tumor requiring active pharmacological or surgical intervention at present;\n* Female patients who are pregnant or breastfeeding;\n* Patients (male or female) of reproductive potential who are unwilling to use or fail to use effective contraceptive measures;\n* Known hypersensitivity to any study drug or any excipient ingredients of these products;\n* Active infection (determined by the investigator);\n* History of immunodeficiency, including positive HIV status, other acquired or congenital immunodeficiency disorders, or history of organ transplantation;\n* Documented history of neurological or psychiatric disorders, including epilepsy or dementia;\n* Documented history of autoimmune diseases (except Hashimoto's thyroiditis or thyroid dysfunction);\n* Any severe comorbidity that, in the investigator's judgment, would compromise patient safety or interfere with the completion of the study.","ALL","18 Years","75 Years",{"count":77,"type":78},43,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a rising trend in immunocompetent patients. First-line high-dose methotrexate-based chemotherapy causes severe toxicities and nearly 50% of patients relapse within 1-2 years, developing relapsed\u002Frefractory (R\u002FR) disease.\n\nTreatment options for R\u002FR PCNSL are scarce, with low response rates, median survival of only 3-6 months, and 5-year survival below 5%. The blood-brain barrier and tumor heterogeneity further worsen outcomes. This prospective, multicenter, single-arm phase II study evaluates the efficacy and safety of pomalidomide, PD-1 inhibitor, and selinexor (PPS) in R\u002FR PCNSL, aiming to provide a new effective treatment.",[84,85],"Primary Central Nervous System Lymphoma (PCNSL)","Diffuse Large B Cell Lymphoma (DLBCL)",[87,88,89,90,28,91],"diffuse large b cell lymphoma","primary central nervous system lymphoma","pomalidomide","PD-1 inhibitor","selinexor","2026-04-10",{"date":94,"type":95},"2026-04-15","ACTUAL",{"date":97,"type":95},"2026-04-01",{"date":99,"type":78},"2028-08-31",{"name":5,"class":6},1]